NCT00572650View on ClinicalTrials.gov

Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

vildagliptin

16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.

Trial Locations (1)

Unknown

Novartis Investigator Site, Kiel